Your browser doesn't support javascript.
loading
Recurrent Cystitis in Women-A Real-World Analysis of Bacteria Spectrum and Resistance Situation for Calculated Therapy.
Spachmann, Philipp J; Radlmaier, Maximilian; Denzinger, Stefan; Burger, Maximilian; Breyer, Johannes; Otto, Wolfgang; Schnabel, Marco J; Vergho, Daniel.
Afiliación
  • Spachmann PJ; Department of Urology, Caritas St. Josef Medical Center Regensburg, University of Regensburg, 93053 Regensburg, Germany.
  • Radlmaier M; Urologie Landau and Urologie Plattling, 94405 Landau/Isar, Germany.
  • Denzinger S; Department of Urology, Caritas St. Josef Medical Center Regensburg, University of Regensburg, 93053 Regensburg, Germany.
  • Burger M; Department of Urology, Caritas St. Josef Medical Center Regensburg, University of Regensburg, 93053 Regensburg, Germany.
  • Breyer J; Department of Urology, Caritas St. Josef Medical Center Regensburg, University of Regensburg, 93053 Regensburg, Germany.
  • Otto W; Department of Urology, Caritas St. Josef Medical Center Regensburg, University of Regensburg, 93053 Regensburg, Germany.
  • Schnabel MJ; Department of Urology, Caritas St. Josef Medical Center Regensburg, University of Regensburg, 93053 Regensburg, Germany.
  • Vergho D; Department of Urology, Caritas St. Josef Medical Center Regensburg, University of Regensburg, 93053 Regensburg, Germany.
Antibiotics (Basel) ; 13(9)2024 Sep 16.
Article en En | MEDLINE | ID: mdl-39335063
ABSTRACT
Recurrent cystitis in women represents an everyday challenge; however, little to no data regarding this population are available. This study aimed to evaluate this collective with respect to a rational calculated antibiotic therapy. Urine cultures and antibiograms from a urological office were retrospectively evaluated from patient data collected between January 2017 and June 2019. The evaluation was conducted using SPSS ©. In total, 84 female patients, who were aged between 18 and 87 years old (median 60 years), suffered from recurrent cystitis. Escherichia coli was found in 53.9% of cases, Staphylococcus aureus and enterococci were each found in 6.7%, and Proteus spp. and Streptococcus agalactiae were each found in 5.6%. The resistance levels to ciprofloxacin (CIP), trimethoprim-sulfamethoxazole (TRS), nitrofurantoin (NIT), and nitroxoline (NOX) were 18.2%, 30.7%, 16.1%, and 12.5% in the tested cases, respectively. Regarding E. coli, resistance to CIP, TRS, and NIT was found in 17.8%, 25%, and 4.2% of the tested cases, and no resistance to NOX was found. The resistance level to CIP was in a tolerable range of <20% in the overall cohort and the E. coli subgroup. More than a quarter of the bacteria were resistant to TRS. The low resistance rates for NIT and NOX are remarkable, promoting the use of these substances if they are not yet used.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Antibiotics (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Antibiotics (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza